
Daily Express Front Page 16th of April 2026
A Cochrane review says Alzheimer’s drugs targeting amyloid offer only a trivial gain in cognition and daily living over 18 months. Charities reject the verdict, arguing lecanemab and donanemab represent genuine progress for patients and research.


